Henriette
Henriette Adriaanse, Boxmeer NL
Patent application number | Description | Published |
---|---|---|
20140178433 | LEPTOSPIRA WITH INCREASED ANTIGENIC MASS - The antigenic mass of | 06-26-2014 |
20150306199 | Leptospira With Increased Antigenic Mass - The antigenic mass of | 10-29-2015 |
Henriette Coetzer, Idstone GB
Patent application number | Description | Published |
---|---|---|
20150019255 | SYSTEMS AND METHODS FOR PRIMARY ADMISSIONS ANALYSIS - An admission analytic engine may search health care records to identify health care providers associated with unnecessary or preventable inpatient admissions based on clinical indicators. Identifying relationships between health care providers and unnecessary or preventable inpatient admissions allows generation of reports highlighting the strengths and weaknesses of the health care providers. Identifying the relationships also allows the admission analytic engine to identify a health care provider accountable for an unnecessary or preventable inpatient admission. | 01-15-2015 |
Henriette De Bod, Roodepoort ZA
Patent application number | Description | Published |
---|---|---|
20120041241 | OLIGOMERISATION OF OLEFINIC COMPOUNDS IN THE PRESENCE OF AN ACTIVATED OLIGOMERISATION CATALYST - This invention relates to the oligomerisation of olefinic compounds in the presence of an activated oligomerisation catalyst. The invention also extends to a particular manner for providing an activated oligomerisation catalyst. According to the present invention, there is provided a process for producing an oligomeric product by the oligomerisation of at least one olefinic compound, the process including (a) providing an activated oligomerisation catalyst by combining, in any order, iii) a source of chromium, ιv) a ligating compound of the formula (R | 02-16-2012 |
Henriette Draborg, Frederikssund DK
Patent application number | Description | Published |
---|---|---|
20100021967 | Alpha Factor Signal Peptide For Producing a Polypeptide - The present invention relates to a method for producing a polypeptide comprising using a variant alpha factor signal peptide having a substitution in position 9 resulting in a substitution of an A to either T, S, H, I, F, E, or G. The invention further relate to nucleic acid constructs comprising a first nucleotide sequence encoding the variant signal peptide and a second nucleotide sequence encoding a polypeptide which is foreign to the first nucleotide sequence. Furthermore, it also relates to expression vectors and host cells comprising said nuclei acid construct. | 01-28-2010 |
Henriette Draborg, Alleroed DK
Patent application number | Description | Published |
---|---|---|
20120122157 | Signal Peptide for Producing a Polypeptide - The present invention relates to a method for producing a polypeptide comprising using a signal peptide, to nucleic acid constructs comprising a first nucleotide sequence encoding the signal peptide and a second nucleotide sequence encoding a polypeptide which is foreign to the first nucleotide sequence. Furthermore, it also relates to expression vectors and host cells comprising the nuclei acid construct. | 05-17-2012 |
20130344573 | Signal Peptide for Producing a Polypeptide - The present invention relates to a method for producing a polypeptide comprising using a signal peptide, to nucleic acid constructs comprising a first nucleotide sequence encoding the signal peptide and a second nucleotide sequence encoding a polypeptide which is foreign to the first nucleotide sequence. Furthermore, it also relates to expression vectors and host cells comprising the nuclei acid construct. | 12-26-2013 |
Henriette Gourdeau, Montreal CA
Patent application number | Description | Published |
---|---|---|
20090062255 | TUMOR-TARGETING EVALUATION METHODOLOGY AND COMPOUNDS RELATED THERETO - The invention relates to a method for evaluating a chemotherapeutic potential of a candidate molecule. In evaluating the candidate molecule, the candidate molecule is tested for its ability to inhibit the in vitro growth of a cancer cell; to bind a cellular receptor produced by a cancer cell, wherein said receptor, such as a peripheral benzodiazepine receptor, is produced in a greater amount by said cancer cell than by a normal cell; and to inhibit the activity of at least one protein member of the MAPK pathway. The invention further relates to dibenzodiazepinone analogues and derivatives thereof. | 03-05-2009 |
20090170837 | METHODS FOR TREATING RAS DRIVEN CANCER IN A SUBJECT - The invention relates to the discovery that the dibenzodiazepinone analogues have growth inhibiting activities on tumorigenic cells that are driven by expression of RAS or mutated RAS. Thus the invention includes methods for inhibiting the activity of RAS using dibenzodiazepinone analogues; methods for inhibiting the growth of a RAS driven cancer cell using dibenzodiazepinone analogues; methods for inhibiting the growth of a RAS driven cancer using dibenzodiazepinone analogues; and methods for treating a subject having a RAS driven cancer using dibenzodiazepinone analogues. | 07-02-2009 |
20110028458 | INHIBITION OF CELL MIGRATION BY A FARNESYLATED DIBENZODIAZEPINONE - The invention relates to the discovery that dibenzodiazepinone analogues have cell migration inhibiting activities on neoplastic and endothelial cells. The migration of neoplastic cells from various tumor types, such as a glioma tumor that may comprise an EGF and/or PTEN mutation, or a Ras-, Raf, or EGFR-mediated tumor, may be inhibited when contacted by the dibenzodiazepinone analogues of the present invention. The invention includes methods for inhibiting migration of a cell in a subject, by contacting a cell with a dibenzodiazepinone analogue of the present invention. | 02-03-2011 |
Henriette Husum Bak-Jensen, Kobenhavn DK
Patent application number | Description | Published |
---|---|---|
20090118285 | USE OF KCNQ-OPENERS FOR TREATING OR REDUCING THE SYMPTOMS OF SCHIZOPHRENIA - The invention relates to a novel method for treating or reducing the symptoms of schizophrenia, said method comprising administering to a host in need thereof an effective amount of a compound able to selectively increase the ion flow through KCNQ potassium channels. Furthermore the invention relates to the use of selective KCNQ potassium channel openers for the preparation of a pharmaceutical composition for treating or reducing the symptoms of schizophrenia and related symptoms, disorders and diseases. Furthermore the invention relates to a method of screening for a compound, which is a selective KCNQ potassium channel opener and which is capable of having an anti-psychotic potential. | 05-07-2009 |
Henriette Jaerger, Heuchelheim DE
Patent application number | Description | Published |
---|---|---|
20150322243 | FILLER MIXTURE FOR THE PRODUCTION OF THERMOPLASTIC SHOE REINFORCEMENT MATERIALS - The present invention relates to a filler mixture made from a bioplastic and a specially selected, renewable natural material, specifically a material consisting of rice husk powder in a volume of up to 50% by weight and polylactic acid powder of up to 70% by weight, which is suitable for the production of thermoplastic reinforcement materials for the footwear industry, primarily for toe caps and counters. Shoe reinforcement materials using the filler mixture according to the invention can be produced both on a double belt system and by extrusion, particularly by coextrusion. | 11-12-2015 |
Henriette Mersebach, Hellerup DK
Patent application number | Description | Published |
---|---|---|
20150126439 | PHARMACEUTICAL COMPOSITION - A combination comprising at least a first insulin-like compound and a second insulin-like compound for treating a condition or a disease in a subject in need thereof where administration of insulin would be of benefit to said subject is described. The combination is administered in an amount to achieve a beneficial glycaemic control in said subject as determined by the levels of HbA | 05-07-2015 |
Henriette Skribek, Godollo HU
Patent application number | Description | Published |
---|---|---|
20130071925 | CELL CULTURE MEDIUM - The present invention relates to a cell culture medium for culturing human cells comprising an anti-coagulated total blood material wherein the hemoglobin level is from about 8 to about 16 g/dl. More particularly, the invention provides a cell culture medium in which cells present in the blood are disrupted and the insoluble remnants of the lysated cells are removed. Further, the invention provides a method for the preparation of a cell culture medium for culturing human cells, according to the invention. | 03-21-2013 |
Henriette Van Praag, Baltimore, MD US
Patent application number | Description | Published |
---|---|---|
20080227829 | Neurogenic compounds - The invention relates to method(s) of use of the compound(s) described herein, e.g. method for stimulating neurogenesis, including in vitro neurogenesis, by contacting neuronal progenitor cells with an effective amount of the compound(s) described herein; method for treatment of a subject in need of treatment with a neurogenic compound; and/or for treatment of a disease or condition associated with damage to the hippocampus. The subject may be a human or a veterinary animal. | 09-18-2008 |
Henriette Weber, Duesseldorf DE
Patent application number | Description | Published |
---|---|---|
20080312123 | HOLLOW BODY WITH A COMPARTMENT, CONTAINING A PORTION OF A WASHING, CLEANING OR RINSING AGENT - A process for producing a detergent portion, comprising the steps of forming one or more dimensionally stable hollow bodies comprising at least one compartment by injection moulding, providing one or more means for compartmentalizing the dimensionally stable hollow bodies, filling the compartment with at least one detersive formulation, and closing the compartment to form a partial or whole enclosure around the detersive formulation. | 12-18-2008 |
Henriette Woldum, Vojie DK
Patent application number | Description | Published |
---|---|---|
20110009350 | Oil-in-Water Formulation of Avermectins - Oil-in-water emulsion formulations (EW) of avermectins based on esters of fatty acids as solvent and the use of such formulations for the control of crop pests. | 01-13-2011 |